PMID- 15341701
OWN - NLM
STAT- MEDLINE
DCOM- 20060706
LR  - 20131121
IS  - 1541-0714 (Electronic)
IS  - 1540-3408 (Linking)
VI  - 3
IP  - 5
DP  - 2004 Sep
TI  - Pathogenesis and management of bleeding in essential thrombocythemia and 
      polycythemia vera.
PG  - 344-51
AB  - Patients with essential thrombocythemia (ET) and polycythemia vera (PV) have a 
      paradoxical predisposition to bleeding and thrombotic complications that are 
      major causes of morbidity and mortality. Bleeding manifestations are often 
      associated with extreme thrombocytosis that may lead to acquired von Willebrand 
      syndrome (AVWS). Symptomatic AVWS, in this instance, is managed by platelet 
      cytoreductive therapy and, in case of a life-threatening situation, platelet 
      apheresis may be of additional value. Qualitative platelet defects are prevalent 
      in PV and ET but have not been consistently linked to clinical bleeding. However, 
      in vitro and in vivo hemostatic defects in these disorders are either 
      precipitated or exacerbated by the use of aspirin or other nonsteroidal 
      anti-inflammatory drugs. Additional patient management issues are raised during 
      systemic anticoagulation and surgery. This review summarizes putative 
      pathogenetic mechanisms of bleeding and their management in ET and PV.
FAU - Elliott, Michelle A
AU  - Elliott MA
AD  - Mayo Clinic, 200 First Street SW, West 10 A, Division of Hematology, Rochester, 
      MN 55905, USA. E-mail: Tefferi.ayalew@mayo.edu
FAU - Tefferi, Ayalew
AU  - Tefferi A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Hematol Rep
JT  - Current hematology reports
JID - 101151358
RN  - 0 (Hemostatics)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/therapeutic use
MH  - Bleeding Time
MH  - Hemostatics/*therapeutic use
MH  - Humans
MH  - Incidence
MH  - Platelet Activation
MH  - Platelet Aggregation
MH  - Polycythemia Vera/blood/*drug therapy/epidemiology/*physiopathology
MH  - Thrombocythemia, Essential/blood/*drug therapy/epidemiology/*physiopathology
RF  - 83
EDAT- 2004/09/03 05:00
MHDA- 2006/07/11 09:00
CRDT- 2004/09/03 05:00
PHST- 2004/09/03 05:00 [pubmed]
PHST- 2006/07/11 09:00 [medline]
PHST- 2004/09/03 05:00 [entrez]
PST - ppublish
SO  - Curr Hematol Rep. 2004 Sep;3(5):344-51.